Moreover, using our core signature consisting of 56 probe sets associated with knock-down of the MLL fusion, we performed hierarchical clustering on gene expression profiling data generated on a large cohort of primary MLL-rearranged infant ALL (n = 71), wild-type MLL pediatric precursor B-ALL (n = 16), and wild-type MLL infant ALL (n = 20) samples, as well as healthy bone marrow samples (n = 13) as non-leukemic controls. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.